Continuing hepatitis B treatment with GST-HG141 and antivirals
Part of Digestive system, Infections clinical trials.
This is a follow-up study for people with chronic hepatitis B who completed an earlier trial of GST-HG141 (a new antiviral drug) combined with standard hepatitis B medications. The study checks if this combination continues to work safely and effectively over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier phase III trial (GST-HG141-III-01) without stopping early and took at least 80% of your doses
- Your liver enzyme (ALT) level must be controlled at 5 times the upper normal limit or below
- Your doctor must believe you can safely continue long-term treatment with this drug combination
- If you can have children, you must use effective birth control from screening through 28 days after stopping the study drug
- You must sign an informed consent form and be able to follow all study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.